SUO 2025: Topline Results from BOND-003 Cohort P – A Multinational , Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-risk, Papillary-only, BCG-unresponsive NMIBC – UroToday

1. SUO 2025: Topline Results from BOND-003 Cohort P – A Multinational , Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-risk, Papillary-only, BCG-unresponsive NMIBC  UroToday
2. CG Oncology Reports Promising Efficacy and Safety Data for Cretostimogene in High-Risk Non-Muscle Invasive Bladder Cancer Trials  Quiver Quantitative
3. BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC  Urology Times
4. CG Oncology announces data from BOND-003 Cohort P, CORE-008 Cohort A  TipRanks
5. Cohort P Data from the BOND-003 Study in BCG-Unresponsive Papillary Bladder Cancer – Mark Tyson  UroToday

Continue Reading